Welcome
Support Centre
12 February 2012 
Current Controlled Trials - Clinical Trials
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   news
Introduction
English introduction Introduction en français Deutsche einleitung
Introducción española Introduzione in italiano
 
Find trials
active registers
mental health register
archived registers
all registers
tips on searching
 
 
Information
about mRCT
mRCT FAQs

DISCLAIMER
The site should not be used to diagnose or treat a health problem. Please consult your doctor.
Terms & conditions

DUPLICATION
Your search result may contain a number of different records for the same trial. This occurs when the same trial is listed in more than one register.

[ ...Back to search results ] [ Print-friendly version ]
The second multi-centre intra-pleural sepsis trial (MIST2), to assess whether DNase or Alteplase, improve pleural fluid drainage in pleural infection
Source of recordUK Trials
ISRCTNISRCTN57454527
Date ISRCTN assigned11/10/2004
Local reference number(s)N/A
Public titleThe second multi-centre intra-pleural sepsis trial (MIST2), to assess whether DNase or Alteplase, improve pleural fluid drainage in pleural infection
Scientific title
AcronymMulti-centre Intra-pleural Sepsis Trial (MIST2)
Disease/condition/study domainPleural infection
Study hypothesisNot provided at time of registration.
Design/methodologyRandomised controlled trial
Research ethics reviewNot provided at time of registration.
Countries of trialUnited Kingdom
Participants - inclusion criteriaPatients with a clinical presentation compatible with pleural infection, have pleural fluid requiring drainage which is either purulent or gram stain positive or culture positive or is acidic with a pH of <7.2.
Participants - exclusion criteriaNot provided at time of registration.
Patient information material
Anticipated start date11/10/2003
Anticipated end date11/10/2007
Status of trialCompleted
Target number of participantsAdded as of 10/09/2007: 210
InterventionsPatients will be randomly assigned in the ratio 1:1:1:1 to either of the following regimes:
Alteplase 10 mg bd (twice a day) intrapleurally + DNase 5 mg bd intrapleurallly; or
Alteplase placebo intrapleurally + DNase 5 mg bd intrapleurally; or
Alteplase 10 mg bd intrapleurally + DNase placebo intrapleurally; or
Alteplase placebo intrapleurally + DNase placebo intrapleurally.
Primary outcome measure(s)Not provided at time of registration.
Secondary outcome measure(s)Not provided at time of registration.
Trial websitehttp://www.ctu.mrc.ac.uk/studies/mist2.asp
Sources of fundingUnrestricted educational grant from Roche UK
Sponsor nameOxford Radcliffe Hospitals NHS Trust (UK)
Sponsor detailsR&D Office
Manor House
The John Radcliffe Hospital
Headley Way
Headington
Oxford
United Kingdom
OX3 9DU
Contact nameDr Robert Davies
Contact detailsOxford Centre for Respiratory Medicine
Churchill Hospital
Old Road
Headington
Oxford
United Kingdom
OX3 7LJ
More informationFor more up-to-date information please go to the ISRCTN link below.
Link to record in ISRCTN RegisterISRCTN57454527
Date last extracted from ISRCTN register17/04/2008
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2012 Current Controlled Trials Ltd. Part of Springer Science+Business Media. | terms & conditions | privacy statement


BioMed Central